Page last updated: 2024-12-08
be 18591
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
BE 18591: isolated from streptomycete; has 2 conjugated pyrrole rings; inhibits growth of MKN-45 human stomach cancer cell line as well as P388 cell line; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 197340 |
MeSH ID | M0227152 |
Synonyms (6)
Synonym |
---|
(z)-n-((3-methoxy-5-(1h-pyrrol-2-yl)-2h-pyrrol-2-ylidene)methyl)-1-dodecanamine |
1-dodecanamine, n-((3-methoxy-5-(1h-pyrrol-2-yl)-2h-pyrrol-2-ylidene)methyl)-, (z)- |
be 18591 |
be-18591 |
147138-01-0 |
n-dodecyl-1-[3-methoxy-5-(1h-pyrrol-2-yl)-1h-pyrrol-2-yl]methanimine |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |